Safety study of Cervarix in females aged 18-25 years in Scotland

• Research type

  Research Study

• Full title

  A phase IV, randomised, open-label, controlled, post-licensure study to evaluate the safety of GlaxoSmithKline Biologicals' HPV-16/18 L1 VLP AS04 vaccine (Cervarix) when administered intramuscularly according to a 0, 1 and 6 month schedule in females aged 18 - 25 years

• IRAS ID

  954

• Contact name

  Frank Sullivan

• Contact email

  frank.sullivan@nygh.on.ca

• Sponsor organisation

  GlaxoSmithKline Biologicals

• Eudract number

  2007-006651-39

• Research summary

  Research Summary not published at request of researcher

• REC name

  East of Scotland Research Ethics Service REC 2

• REC reference

  08/S0501/94

• Date of REC Opinion

  22 Dec 2008

• REC opinion

  Further Information Favourable Opinion